FDA Updates Animal Meds List from Last Fall
Published Date: 1/21/2025
Rule
Summary
The FDA is updating rules about new animal medicines approved or changed in late 2024. These updates affect drug makers and vets by making the rules clearer and reflecting recent approvals, withdrawals, and sponsor changes. This helps everyone know what’s new and when, keeping animal health on track without surprises.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Regulations Updated for Late‑2024 Drug Actions
The FDA updated animal drug rules to reflect application actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) that occurred in October, November, and December 2024. This update records recent approvals, withdrawals, sponsor changes, and sponsor address changes so drug makers and veterinarians can see the current official status.
Rule Wording Improved for Clarity
The FDA amended the animal drug regulations to improve their accuracy and readability. These wording and formatting changes are intended to make the rules easier to understand for drug makers and veterinarians who use them.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10371 — Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal
The FDA is renewing its Drug Safety and Risk Management Advisory Committee for two more years, keeping it active until May 31, 2028. This committee helps the FDA make smart decisions about drug safety and risks, protecting everyone who uses medicines. No new costs or big changes, just a continued commitment to keeping drugs safe and sound.
2026-10372 — Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
The FDA wants your thoughts on how they collect info about making custom human drugs under special rules (Sections 503A and 503B). This affects pharmacies and drug makers who mix medicines just for patients. You’ve got until July 27, 2026, to share your comments—no cost changes yet, just a chance to help shape the paperwork process!
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
Previous / Next Documents
Previous: 2025-01215 — Interim Final Determination To Defer Sanctions, San Joaquin Valley Unified Air Pollution Control District
The EPA is giving the San Joaquin Valley air district a break by pausing penalties after they fixed problems with their pollution control rules. This means businesses and the community get more time while the new rules get approved, keeping things on track without extra costs or fines for now. It’s a win for clean air and local progress!
Next: 2025-01367 — Modification of Class E Airspace; Crosby Municipal Airport, Crosby, ND
Hey pilots and air traffic fans! The rules describing the Class E airspace around Crosby Municipal Airport in North Dakota are getting a little update—but don’t worry, the actual airspace and how you fly there won’t change. This is just a paperwork tweak with no impact on your flights or costs.